Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Vipoma 2Somatostatinoma 2Rectal Neoplasms 2Insulinoma 2Glucagonoma 2Gastrinoma 2Colorectal Neoplasms 2Carcinoma, Islet Cell 2Thymoma 1Neuroendocrine Tumors 1Neoplasms 1Meningioma 1Drug-Related Side Effects and Adverse Reactions 1Diarrhea 1Colonic Neoplasms 1Breast Neoplasms 1Anus Neoplasms 1Adenoma, Islet Cell 1

Interventions

Fluorouracil 8Cisplatin 5Radiotherapy 4Mitomycin 4Light Coagulation 3dehydroftorafur 2Watchful Waiting 2Taxes 2Radiotherapy, Intensity-Modulated 2Paclitaxel 2Cetuximab 2Carboplatin 2Capecitabine 2Biopsy 2Vorinostat 1Specimen Handling 1Polymerase Chain Reaction 1Platinum 1Octreotide 1Observation 1Mitozytrex 1Magnetic Resonance Spectroscopy 1Laser Therapy 1Imiquimod 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1Gene Expression Profiling 1Fluorodeoxyglucose F18 1DNA Methylation 1Cidofovir 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Anus Neoplasms × Octreotide × Clear all
NCT00075868 2015-11-17

Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer

Radiation Therapy Oncology Group

Phase 3 Completed
233 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡